Project Grant P01CA291697
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$2.5M
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Research Manpower" (CFDA 93.398), awarded a Project Grant in the amount of $145,336 to the Sloan-Kettering Institute for Cancer Research located in New York. The grant, titled "Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors," will fund research focused on reprogramming hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven...
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...
This Project Grant award, with a total funding amount of $689,914, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research federal grant program (CFDA 93.395). The award aims to delineate the mechanisms by which the concurrent loss-of-function mutations in the STK11 and KEAP1 genes confer resistance to ferroptosis-mediated cell death in aggressive subtypes of non-small cell lung cancer (NSCLC). The research will define the molecular and immune features...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $730,398 to the Sloan-Kettering Institute for Cancer Research to investigate the relationship between leptomeningeal cancer cell growth and inflammatory signaling in the leptomeningeal space. The research aims to mechanistically dissect the CXCL1-CXCR2 signaling axis within the leptomeningeal space, identify cancer cell signals that provoke leptomeningeal CXCL1 generation, and...
The National Cancer Institute (NCI) awarded a $238,722 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, awarded on August 18, 2025, will fund research to investigate the role of mutagenic DNA repair mechanisms, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. The research aims to define the specific mechanisms by which...
The National Cancer Institute (NCI) awarded a $2,679,816 Project Grant (CFDA 93.396 Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai. The 5-year grant, effective August 1, 2025, will support an integrated research program focused on understanding the role of mutant p53 proteins in tumor progression, invasion, and metastasis. The program consists of four interrelated projects that will use systematic studies, molecular mechanisms, and transcriptional regulation approaches...
This Project Grant award of $656,304 from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) supports comprehensive research at Weill Medical College of Cornell University to better understand the fundamental biological mechanisms underlying cancer development, progression, and potential interventions. The research aims to: (i) determine how nuclear accumulation of GSK3, upon suppression of mTORC1 signaling, regulates chromatin remodeling and DNA damage repair;...
This federal Project Grant award for $704,000.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the Sloan-Kettering Institute for Cancer Research in New York, NY. The research aims to investigate the role of the NF-I/A transcription factor in regulating fatty acid metabolism in kidney cancer. This multi-year project will run from September 1, 2024 to August 31, 2028. As the prime grantee, the Sloan-Kettering...
The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research in New York. The goal of this 5-year project is to determine how specific metabolic configurations in lung adenocarcinoma (LUAD) cancer cells support the emergence and maintenance of treatment-resistant cell states. The research team will manipulate components of the tricarboxylic acid (TCA) cycle in mouse and...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...